RECBIO-B (02179) plans to issue approximately 70.1393 million new H shares to Hong Kong Huyou Health Co., Ltd. at a premium of approximately 28.21%, raising net proceeds of approximately HK$344.5 million.
RECBIO-B (02179) announced that on November 18, 2026, the company plans to issue approximately 70.1393 million new H shares to Hong Kong Huyou Health Co., Ltd. at a subscription price of HK$5.00 per subscription share, representing a premium of approximately 28.21% over the closing price of HK$3.90 per H share as quoted on the Stock Exchange on the last trading day, for a total consideration of approximately HK$351 million.
RECBIO-B (02179) announced that on November 18, 2026, the company plans to issue approximately 70.1393 million new H shares to Hong Kong Huyou Health Co., Ltd. at a subscription price of HK$5.00 per subscription share, representing a premium of approximately 28.21% over the closing price of HK$3.90 per H share as quoted on the Stock Exchange on the last trading day, for a total consideration of approximately HK$351 million.
The net proceeds from the subscription are approximately HK$344.5 million, of which approximately 30% will be used for pre-launch preparation and commercial production layout of the recombinant shingles vaccine REC610; 30% for research and development activities and industrialization construction of the nine-valent HPV vaccine REC603; 20% for supplementing working capital; and 20% for repaying principal and interest owed to financial institutions that are not shareholders of the company.
As at the date of this announcement, Yangzijiang Pharmaceutical holds a total of approximately 143 million domestic shares, accounting for approximately 22.86% of the issued shares, and is therefore a substantial shareholder and connected person of the company under the Listing Rules. As the subscriber is a wholly-owned subsidiary of Yangzijiang Pharmaceutical, the subscriber is an associate of Yangzijiang Pharmaceutical and is also a connected person of the company under the Listing Rules.
Related Articles

SA SA INT'L (00178) will pay an interim dividend of HK$0.04 per share on December 18.

SSY GROUP (02005): Low-calcium Peritoneal Dialysis Solution (Bicarbonate G1.5%) and Other Drugs Obtain Drug Production Registration Approval

SA SA INT'L (00178) announces interim results, profit attributable to shareholders HK$170 million, up 239.14% year-on-year; sales performance in core markets Hong Kong and Macau improved significantly.
SA SA INT'L (00178) will pay an interim dividend of HK$0.04 per share on December 18.

SSY GROUP (02005): Low-calcium Peritoneal Dialysis Solution (Bicarbonate G1.5%) and Other Drugs Obtain Drug Production Registration Approval

SA SA INT'L (00178) announces interim results, profit attributable to shareholders HK$170 million, up 239.14% year-on-year; sales performance in core markets Hong Kong and Macau improved significantly.






